824-82-8

Basic information

• Product Name: Cyclohexanamine, N-cyclopropyl-
• CAS NO: 824-82-8
• Molecular Formula: C9H17N
• Molecular Weight: 139.241
• Mol File: 824-82-8.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Cyclohexanamine, N-cyclopropyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanamine, N-cyclopropyl-(824-82-8)
• EPA Substance Registry System: Cyclohexanamine, N-cyclopropyl-(824-82-8)

Safety Data

• Hazardous Substances Data: 824-82-8(Hazardous Substances Data)

Upstream product

• 108-94-1 cyclohexanone 
• 765-30-0 Cyclopropylamine 
• 110-82-7 cyclohexane 

Downstream Products

• 872420-62-7 1-(4-chlorophenyl)-N-cyclohexyl-N-cyclopropylcyclopropanecarboxamide 
• 1373032-26-8 C₂₃H₃₁ClN₄O₄S 

Relevant articles and documents

4-Substituted 2-amino-3,4-dihydroquinazolines with a 3-hairpin turn side chain as novel inhibitors of BACE-1

Herein, we report the identification, design, and synthesis of a series of 4-substituted 2-amino-3,4-dihydroquinazolines with hairpin turn side chains as novel inhibitors of BACE-1. The dihydroquinazoline derivatives were rationally designed by modifying the amide group and relocating the α -hydrophobic substituent on the hairpin turn side chain of lead compound 2 to the C4-position on the 3,4-dihydroquinazoline scaffold to facilitate interactions with the S1, S2 and S1′ subsites of BACE-1. Among these derivatives, two compounds exhibited potent BACE-1 inhibitory activity: 4-methyl-substituted (22a, BACE-1 CFA IC50 = 0.38 μM; BACE-1 WCA IC50 = 0.14 μM) and 4-cyclohexylmethyl-substituted (22b, BACE-1 CFA IC50 = 0.49 μM; BACE-1 WCA IC50 = 0.14 μM) 2-amino-3,4-dihydroquinazoline, each bearing a side chain of N-cyclohexyl-N-((1-methyl-1H-pyrazol-4-yl)methyl amide. The results suggest that the structural modifications maintain the hairpin turn topology similar to that of compound 2 and provide an additional interaction with the S2 subsite.

A biocatalytic cascade for the amination of unfunctionalised cycloalkanes

Here we describe a one-pot, three-enzyme, cascade involving a cytochrome P450 monooxygenase, an alcohol dehydrogenase and a reductive aminase for the synthesis of secondary amines from cycloalkanes. Amine product concentrations of up to 19.6 mM were achieved. The preparative scale amination of cyclohexane was also demonstrated with a space-time yield of 2 g L-1 d-1.

Discovery of novel, potent benzamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model

We report the discovery of potent benzamide inhibitors of 11β-hydroxysteroid dehydrogenase (11β-HSD1). The optimization and correlation of in vitro and in vivo metabolic stability will be described. Through modifications to our initial lead 2, we discovered pyridyl compound 13. This compound has a favorable pharmacokinetic profile across three species and showed a dose-dependent decrease in adipose 11β-HSD1 activity in a monkey ex vivo pharmacodynamic model.